Navigation Links
InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development
Date:2/9/2012

ylvania School of Medicine. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation, the statements related to the achievement of InterMune's Vision 2015 Strategic Plan, the growth of our scientific endeavors, the expansion of our product portfolio and InterMune's clinical development plans.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. InterMune Appoints Angus C. Russell to Board of Directors
3. InterMune to Release Third Quarter Financial Results on November 3
4. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
5. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
6. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
7. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Third Quarter 2010 Financial Results
10. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
11. InterMune to Release Second Quarter Financial Results on July 27
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ... ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, Schedule ... ) today, and provides an update for shareholders detailing why ... is requested. Dear Shareholders, As we ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... MASI ), the inventor of Pulse CO-Oximetry(TM) ... that three new independent studies demonstrating the clinical accuracy ... continuous measure of patient fluid status and responsiveness were ... (ESA) Annual Congress in Milan, Italy. , ...
... in End of Phase 2a Meeting , , ... VIAP ), a biotechnology company focused on the development ... announced today that an end of Phase 2a meeting for ... the U.S. Food and Drug Administration (FDA). The Company ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Who: The American Society for Radiation Oncology (ASTRO) the world,s ... 10,000 members who use radiation to treat cancer and other ... ASTRO,s 53rd Annual Meeting: "Patient-focused, High-quality, Multidisciplinary Care." ... a.m. - 4:30 p.m. Note: Press room days have changed. ...
... (HealthDay News) -- Older, heavier women tend to have fewer ... study suggests. The study included 52 women who experienced ... The women,s body fat percentage, waist circumference and ... skin monitor and electronic diary were used to track their ...
... News) --,Hospitalized children who carry a dangerous type of ... still at high risk for developing full-blown infections, a ... aureus (MRSA) -- is linked to more than 18,600 ... Hopkins Children,s Center researchers examined the medical records of ...
... defibrillators, simpler may be safer, even though more complex machines ... a new study from a team that included University of ... reviewed more than 100,000 records of cardiac patients. They found ... with devices that require electrical leads to be attached to ...
... [EMBARGOED FOR AUG. 31, 2011, ARLINGTON, Va.] Immunizations, ... to protect children from life-threatening pneumonia, according to new ... the Infectious Diseases Society of America (IDSA)., The guidelines, ... pneumonia (CAP) in infants and children, place preventing bacterial ...
... , TUESDAY, Aug. 30 (HealthDay News) -- Changes in diet ... researchers say. Their findings, published online Aug. 30 in ... virus populations in the gut, how they differ from person ... "Our bodies are like coral reefs, inhabited by ...
Cached Medicine News:Health News:Being Heavier May Mean Fewer Hot Flashes for Women Over 60 2Health News:Kids Carrying MRSA Germ Prone to Serious Infection: Study 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 3Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 4
... new system to help you meet the ... system's one-piece design creates a broad area ... radiographic assessment. The slotted superior and inferior ... column and are flared outward for greater ...
... With 36 joules delivered energy, the Atlas+ HF ... patient safety, programming flexibility, comfort, and quality of ... most powerful ICD offering cardiac resynchronization therapy (CRT), ... 81 gram and 40 cc physiologic-shaped can. In ...
... Intramedullary fixation has greatly ... tibial fractures. The Biomet Low ... indicated in the treatment of ... metastatic disease with pathologic or ...
... The Elite™ Premium Shoulder Instrument ... flexibility in arthroscopic and mini-open ... cuff and Bankart repair. Smith ... been designed to facilitate an ...
Medicine Products: